Other congenital malformations of spinal cord

Q17_OTHER_CONGEN_MALFO_SPINAL_CORD

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — Q06
  • Cause of death: ICD-10 — Q06

2 out of 7 registries used, show all original rules.

57

4. Check minimum number of events

None

57

5. Include endpoints

None

57

6. Filter based on genotype QC (FinnGen only)

52

Control definitions (FinnGen only)

Control exclude
Q17_CONGEN_MALFO_NERVOUS_SYSTEM

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF4
Parent code in ICD-10
Q0
Name in latin
Aliae malformationes congenitae medullae spinalis

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 561 319 242
Only index persons 443 266 177
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.01
Only index persons 0.01 0.01 0.01
Median age at first event (years)
Whole population - 14.91 10.34
Only index persons 22.35 26.14 16.64

-FinnGen-

Key figures

All Female Male
Number of individuals 52 33 19
Unadjusted period prevalence (%) 0.01 0.01 0.01
Median age at first event (years) 46.52 47.08 45.54

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
57
Matched controls
570
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
Q06.8
ICD-10 Finland
Other specified congenital malformations of spinal cord
+∞
31.1
27
*
Q06.9
ICD-10 Finland
Congenital malformation of spinal cord, unspecified
+∞
15.3
14
*
ABE99
NOMESCO Finland
Other operation for spinal malformation
+∞
9.6
9
*
XKC03
NOMESCO Finland
Water cystometry
21.2
8.5
12
7
UKC02
NOMESCO Finland
Cystoscopy
7.7
7.6
18
32
S97
ICPC
Chronic ulcer skin
12.5
7.5
13
13
Q06.3
ICD-10 Finland
Other congenital cauda equina malformations
+∞
7.4
7
*
Q05.9
ICD-10 Finland
Spina bifida, unspecified
+∞
7.4
7
*
204
Kela drug reimbursment
Leukemia lymphatica
23.7
7.4
10
5
L17
ICPC
Foot/toe symptom/complaint
4.4
7.1
30
115
G04AC01, ,
ATC
16.9
6.7
10
7
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
4.9
6.5
18
49
QDB10
NOMESCO Finland
Major dressing of wound of skin of lower limb
20.9
6.5
9
5
G95.0
ICD-10 Finland
Syringomyelia and syringobulbia
+∞
6.4
6
*
TKC22
NOMESCO Finland
Catheterisation instruction
+∞
6.4
6
*
XKD06
NOMESCO Finland
Physiologic investigation of micturition
14.8
6.4
10
8

TimeCodeWAS

↥

TimeCodeWAS is a tool for exploring time-dependent associations between an endpoint and health codes (diagnoses, lab tests, procedures, etc.).

The TimeCodeWAS analysis is done in three steps:

  1. Build a matched case-control set for this endpoint. Each case is matched to 5–10 controls on sex and year of birth, and controls must be at risk at the same age as the case's age of onset. TimeCodeWAS allows for controls to be reused.
  2. Count cases and controls. For each health code, and for each time window: tally the counts into a 2×2 table. To be eligible in a time window, a case or control must have data coverage for at least 50% of that time window.
  3. Perform association tests. If all cells of the 2×2 table have N≥10, then a χ² test is performed, otherwise a Fisher's exact test is done. The corresponding p-value and confidence interval are reported below, along with the standard odds ratio when a χ² test is done, or Fisher's MLE odds ratio otherwise.

TimeCodeWAS currently uses the same default set of time windows for all the endpoints. Please reach out to us if you have suggestions for better time windows for some endpoints. The default time windows are: TimeCodeWAS time windows

Sort & Filter
Sort
Odds Ratio
among windows:
Filter
Code & OMOP
Cases and controls with code
in
Odds Ratio
in
OMOP Concept
Code (OMOP Vocabulary) [OMOP Concept ID]
OMOP Concept Class / OMOP Domain
Odds Ratio
TimeCodeWAS O.R. time legend
Cases and controls with code
TimeCodeWAS Cases and Controls percentages time legend
Physical Medicine And Rehabilitation
25 (Medicare Specialty) [38004468]
Physician Specialty / Provider
1.5e+00 2.4e+00 — 1.0e+50 — 3.6e+00 —
24.07%/6.49% 24.07%/2.78% —/— 11.11%/0.00% —/— 27.45%/0.99% —/—
Neurosurgery
14 (Medicare Specialty) [38004459]
Physician Specialty / Provider
2.2e+00 2.8e+00 — 1.0e+50 — — —
16.67%/2.23% 22.22%/1.67% —/— 55.56%/0.00% —/— —/— —/—
Paediatric neurology
421 (HES Specialty) [44777781]
Physician Specialty / Provider
2.2e+00 2.4e+00 — — — 2.6e+00 —
11.11%/1.30% 9.26%/0.93% —/— —/— —/— 11.76%/0.99% —/—
Pediatric Surgery
OMOP4822020 (ABMS) [45756819]
Physician Specialty / Provider
2.0e+00 2.4e+00 — — — 2.6e+00 —
12.96%/2.04% 9.26%/0.93% —/— —/— —/— 11.76%/0.99% —/—
Case Management Agency
251B00000X (NUCC) [38004193]
Visit / Visit
3.0e-01 3.2e-01 3.8e-01 2.4e+00 6.3e-01 6.1e-01 —
59.26%/51.76% 55.56%/47.68% 24.07%/17.81% 20.37%/2.23% 27.78%/16.98% 60.78%/45.73% —/—
Physiotherapy
R4110 (NCSPfi) [2001310233]
NCSPfi Level 3 / Observation
— — — — — 2.4e+00 —
—/— —/— —/— —/— —/— 11.76%/1.19% —/—
Cystoscopy
UKC02 (NCSPfi) [2001306005]
NCSPfi Level 3 / Procedure
2.4e+00 — — — — — —
9.26%/0.93% —/— —/— —/— —/— —/— —/—
ciprofloxacin; oral, parenteral
J01MA02 (ATC) [21603009]
ATC 5th / Drug
— — — — — 2.4e+00 —
—/— —/— —/— —/— —/— 9.80%/0.99% —/—
Scheduled procedure
ZXD10 (NCSPfi) [2001311387]
NCSPfi Level 3 / Procedure
9.8e-01 — — — — 2.2e+00 —
11.11%/4.45% —/— —/— —/— —/— 13.73%/1.79% —/—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
15
43
4.38
5.01
9.2
11.2
7.40
7.43
ph
—
8
30
32
167
3.09
4.20
3.0
2.4
—
—
—
0
0
10
19
6.14
4.04
5.5
12.9
24.36
26.42
mmol/l
—
10
19
9
20
5.13
3.27
6.9
15.1
96.22
94.52
%
—
9
20
24
120
2.73
3.23
4.8
5.4
95.04
89.92
%
0.61
24
120
20
92
2.81
3.14
6.2
3.2
589.65
553.68
mosm/kgh2o
0.39
20
82
9
22
4.65
3.03
6.6
13.5
0.56
0.75
%
—
9
22
26
142
2.53
2.87
11.3
3.8
—
—
estimate
—
0
0
38
250
2.56
2.79
4.1
2.8
—
—
estimate
—
0
0
26
151
2.33
2.43
10.4
2.8
—
—
—
0
0
14
61
2.72
2.37
5.3
9.3
105.50
104.21
mmol/l
0.46
14
61
21
113
2.36
2.32
8.7
4.5
—
—
—
0
0
8
25
3.55
2.19
2.0
2.0
—
—
—
0
0
16
81
2.36
1.99
11.0
5.1
1.86
1.53
e6/l
0.15
11
47
28
188
1.96
1.67
1.7
1.9
101.85
95.48
pmol/l
—
10
93
37
274
2.00
1.65
8.1
4.0
0.00
0.00
estimate
—
7
45
28
189
1.95
1.63
1.4
1.6
—
—
—
0
0
29
199
1.93
1.61
14.4
5.3
48.05
26.63
e6/l
0.43
24
137
11
52
2.38
1.56
32.9
13.1
25.45
25.38
mmol/l
0.03
11
52
44
352
2.10
1.51
11.6
4.4
—
—
—
0
0
10
179
0.46
1.37
2.5
2.7
—
—
—
0
0
40
318
1.86
1.29
3.7
3.6
—
—
—
0
0
30
223
1.73
1.18
6.0
3.6
6.53
6.31
ph
0.60
18
111
12
68
1.97
1.11
5.8
1.6
—
—
—
0
0
7
33
2.27
1.10
21.3
5.5
123.71
129.36
g/l
—
7
33
5
22
2.39
1.05
4.8
6.5
36.84
36.97
°c
—
5
22
7
35
2.14
1.04
38.3
12.2
—
—
—
0
0
34
271
1.63
0.96
8.2
3.9
0.00
0.00
estimate
—
6
46
10
57
1.91
0.90
11.6
11.1
—
—
—
0
0
34
274
1.60
0.90
8.4
4.0
0.00
0.00
estimate
—
7
45
11
66
1.83
0.86
5.4
2.1
—
—
—
0
0
14
93
1.67
0.79
4.9
3.2
19.67
172.35
ng/l
—
9
55
9
57
1.69
0.76
3.2
1.5
—
—
—
0
0
7
41
1.80
0.73
8.3
11.2
0.66
1.37
mmol/l
—
7
41
5
26
2.01
0.72
29.2
6.5
23.50
24.08
mmol/l
—
5
26
5
27
1.93
0.70
15.6
5.0
—
—
—
0
0
5
27
1.93
0.70
2.2
4.1
0.72
0.75
%
—
5
27
5
28
1.86
0.68
2.2
4.0
0.70
1.46
%
—
5
28
19
143
1.49
0.64
4.4
3.6
0.00
0.00
estimate
—
5
42
0
22
0.00
0.60
0.0
1.6
—
0.29
—
0
8
7
47
1.56
0.50
10.7
7.0
24.83
24.13
mmol/l
—
7
47
11
150
0.67
0.50
2.0
3.3
—
—
—
0
0
10
139
0.66
0.49
3.5
2.1
—
—
—
0
0
10
69
1.54
0.48
2.8
3.3
13.47
24.93
%
—
10
64
7
50
1.46
0.47
1.7
1.5
—
—
—
0
0
11
79
1.49
0.45
3.5
3.2
8.26
14.52
umol/l
3.66
11
74
5
32
1.62
0.43
3.8
4.1
—
—
—
0
0
14
107
1.41
0.42
2.9
5.2
1.83
1.98
ug/l
0.10
14
93
0
16
0.00
0.42
0.0
6.8
—
—
—
0
0
9
65
1.46
0.41
1.3
1.1
—
—
—
0
0
15
117
1.38
0.40
2.9
2.3
1.96
2.68
mg/l
1.22
15
105
7
55
1.31
0.31
1.1
1.2
—
—
—
0
0
7
56
1.28
0.31
2.0
2.6
4.81
8.59
e9/l
—
7
51
22
252
0.79
0.30
10.0
11.6
0.00
0.00
e9/l
-0.00
17
204
8
62
1.34
0.30
1.0
1.3
—
—
—
0
0
28
251
1.23
0.26
3.4
3.3
69.21
82.82
ug/l
0.44
28
243
21
184
1.22
0.24
4.9
7.8
—
—
—
0
0
0
11
0.00
0.21
0.0
4.2
—
5.22
—
0
11
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
4.2
—
8.49
—
0
11
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
4.0
—
15.40
—
0
10
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.6
—
—
—
0
0
34
317
1.18
0.18
7.0
12.1
5.01
3.96
e9/l
0.92
29
276
10
117
0.82
0.14
2.6
1.8
—
—
—
0
0
7
82
0.83
0.07
2.3
1.8
—
—
—
0
0
15
138
1.12
0.07
2.3
2.5
141.20
120.21
u/l
0.16
15
132
17
178
0.94
0.02
2.8
1.9
—
—
—
0
0
12
117
1.03
0.00
4.2
4.9
—
—
—
0
0
13
127
1.03
0.00
1.2
1.8
2.17
2.00
g/l
—
6
68
0
6
0.00
0.00
0.0
1.3
—
200.67
—
0
6
0
6
0.00
0.00
0.0
3.3
—
0.67
—
0
6
0
6
0.00
0.00
0.0
5.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
3.7
—
30.67
—
0
6
0
6
0.00
0.00
0.0
12.8
—
7.50
—
0
6
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
3.3
—
15.17
—
0
6
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
4.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
3.7
—
15.47
—
0
9
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
26.50
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
19
190
1.00
-0.00
7.7
8.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
9
90
1.00
-0.00
2.0
1.9
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
7.12
—
0
5
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
108.40
—
0
5
8
82
0.97
-0.00
2.3
1.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
5.3
—
1.44
—
0
9
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint Q17_OTHER_CONGEN_MALFO_SPINAL_CORD and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have Q17_OTHER_CONGEN_MALFO_SPINAL_CORD.

N-year risk Females Males
1 No data No data
5 No data No data
10 No data No data
15 No data No data
20 No data No data

Relationships between endpoints

↥

Index endpoint: Q17_OTHER_CONGEN_MALFO_SPINAL_CORD – Other congenital malformations of spinal cord

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data